S&P 500   3,150.21 (+1.05%)
DOW   28,026.34 (+1.26%)
QQQ   204.96 (+1.25%)
AAPL   270.79 (+1.96%)
FB   200.90 (+0.77%)
MSFT   151.17 (+0.83%)
AMZN   1,751.05 (-0.55%)
NVDA   211.95 (+1.21%)
MU   47.87 (+2.68%)
BABA   201.47 (+0.74%)
GE   11.01 (+2.04%)
TSLA   337.22 (+1.26%)
AMD   39.63 (-0.15%)
ACB   2.42 (-0.82%)
F   9.03 (+1.12%)
BAC   33.78 (+2.09%)
DIS   148.13 (+0.47%)
S&P 500   3,150.21 (+1.05%)
DOW   28,026.34 (+1.26%)
QQQ   204.96 (+1.25%)
AAPL   270.79 (+1.96%)
FB   200.90 (+0.77%)
MSFT   151.17 (+0.83%)
AMZN   1,751.05 (-0.55%)
NVDA   211.95 (+1.21%)
MU   47.87 (+2.68%)
BABA   201.47 (+0.74%)
GE   11.01 (+2.04%)
TSLA   337.22 (+1.26%)
AMD   39.63 (-0.15%)
ACB   2.42 (-0.82%)
F   9.03 (+1.12%)
BAC   33.78 (+2.09%)
DIS   148.13 (+0.47%)
S&P 500   3,150.21 (+1.05%)
DOW   28,026.34 (+1.26%)
QQQ   204.96 (+1.25%)
AAPL   270.79 (+1.96%)
FB   200.90 (+0.77%)
MSFT   151.17 (+0.83%)
AMZN   1,751.05 (-0.55%)
NVDA   211.95 (+1.21%)
MU   47.87 (+2.68%)
BABA   201.47 (+0.74%)
GE   11.01 (+2.04%)
TSLA   337.22 (+1.26%)
AMD   39.63 (-0.15%)
ACB   2.42 (-0.82%)
F   9.03 (+1.12%)
BAC   33.78 (+2.09%)
DIS   148.13 (+0.47%)
S&P 500   3,150.21 (+1.05%)
DOW   28,026.34 (+1.26%)
QQQ   204.96 (+1.25%)
AAPL   270.79 (+1.96%)
FB   200.90 (+0.77%)
MSFT   151.17 (+0.83%)
AMZN   1,751.05 (-0.55%)
NVDA   211.95 (+1.21%)
MU   47.87 (+2.68%)
BABA   201.47 (+0.74%)
GE   11.01 (+2.04%)
TSLA   337.22 (+1.26%)
AMD   39.63 (-0.15%)
ACB   2.42 (-0.82%)
F   9.03 (+1.12%)
BAC   33.78 (+2.09%)
DIS   148.13 (+0.47%)
Log in

NASDAQ:ANCN - ANCHIANO THERAP/S Stock Price, Forecast & News

$1.59
-0.02 (-1.24 %)
(As of 12/6/2019 12:54 PM ET)
Today's Range
$1.58
Now: $1.59
$1.83
50-Day Range
$1.31
MA: $1.96
$2.48
52-Week Range
$1.24
Now: $1.59
$11.50
Volume2,620 shs
Average Volume23,340 shs
Market Capitalization$11.80 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Anchiano Therapeutics Ltd, a clinical-stage biotechnology company, develops gene therapies to treat early-stage bladder cancer. It is primarily developing Inodiftagene that is in various clinical trials for the treatment of non-muscle-invasive bladder cancer. The company was formerly known as BioCancell Ltd. and changed its name Anchiano Therapeutics Ltd in July 2018. The company was founded in 2004 and is headquartered in Jerusalem, Israel.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ANCN
CUSIPN/A
CIKN/A
Phone972-2548-6555

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Net Income$-13,280,000.00

Miscellaneous

Employees19
Market Cap$11.80 million
Next Earnings Date3/23/2020 (Estimated)
OptionableNot Optionable

Receive ANCN News and Ratings via Email

Sign-up to receive the latest news and ratings for ANCN and its competitors with MarketBeat's FREE daily newsletter.


ANCHIANO THERAP/S (NASDAQ:ANCN) Frequently Asked Questions

What is ANCHIANO THERAP/S's stock symbol?

ANCHIANO THERAP/S trades on the NASDAQ under the ticker symbol "ANCN."

How were ANCHIANO THERAP/S's earnings last quarter?

ANCHIANO THERAP/S (NASDAQ:ANCN) released its quarterly earnings results on Monday, August, 5th. The company reported ($0.05) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($0.17) by $0.12. View ANCHIANO THERAP/S's Earnings History.

When is ANCHIANO THERAP/S's next earnings date?

ANCHIANO THERAP/S is scheduled to release their next quarterly earnings announcement on Monday, March 23rd 2020. View Earnings Estimates for ANCHIANO THERAP/S.

What price target have analysts set for ANCN?

3 brokerages have issued twelve-month target prices for ANCHIANO THERAP/S's stock. Their forecasts range from $12.00 to $16.00. On average, they expect ANCHIANO THERAP/S's share price to reach $14.00 in the next year. This suggests a possible upside of 780.5% from the stock's current price. View Analyst Price Targets for ANCHIANO THERAP/S.

What is the consensus analysts' recommendation for ANCHIANO THERAP/S?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ANCHIANO THERAP/S in the last year. There are currently 3 hold ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for ANCHIANO THERAP/S.

Has ANCHIANO THERAP/S been receiving favorable news coverage?

Press coverage about ANCN stock has trended somewhat positive recently, according to InfoTrie Sentiment. The research firm rates the sentiment of news coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. ANCHIANO THERAP/S earned a daily sentiment score of 1.7 on InfoTrie's scale. They also assigned headlines about the company a news buzz of 2.0 out of 10, meaning that recent news coverage is very unlikely to have an effect on the stock's share price in the near term. View News Stories for ANCHIANO THERAP/S.

Who are some of ANCHIANO THERAP/S's key competitors?

What other stocks do shareholders of ANCHIANO THERAP/S own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ANCHIANO THERAP/S investors own include Cranswick (CWK), Cairn Energy (CNE), Clarkson (CKN), Charter Court Financial Services Grp (CCFS), Close Brothers Group (CBG), Bodycote (BOY), British American Tobacco Plc Ads (BATS), AstraZeneca (AZN), Avast (AVST) and Asiamet Resources (ARS).

Who are ANCHIANO THERAP/S's key executives?

ANCHIANO THERAP/S's management team includes the folowing people:
  • Dr. Frank G. Haluska, Pres, CEO & Director (Age 60)
  • Mr. Jonathan Burgin, CFO & COO (Age 58)
  • Mr. Ronald K. Knickerbocker, Sr. VP of Clinical Devel. & Data Sciences (Age 53)
  • Prof. Abraham Hochberg, Co-Founder & Chief Scientific Officer (Age 81)
  • Dr. Michal Gilon Ohev-Zion, VP of R&D (Age 41)

When did ANCHIANO THERAP/S IPO?

(ANCN) raised $35 million in an initial public offering (IPO) on Tuesday, February 12th 2019. The company issued 2,400,000 shares at a price of $14.55 per share. Oppenheimer acted as the underwriter for the IPO and Ladenburg Thalmann was co-manager.

Who are ANCHIANO THERAP/S's major shareholders?

ANCHIANO THERAP/S's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Phoenix Holdings Ltd. (0.35%) and Virtu Financial LLC (0.18%).

Which major investors are buying ANCHIANO THERAP/S stock?

ANCN stock was purchased by a variety of institutional investors in the last quarter, including Phoenix Holdings Ltd. and Virtu Financial LLC.

How do I buy shares of ANCHIANO THERAP/S?

Shares of ANCN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is ANCHIANO THERAP/S's stock price today?

One share of ANCN stock can currently be purchased for approximately $1.59.

How big of a company is ANCHIANO THERAP/S?

ANCHIANO THERAP/S has a market capitalization of $11.80 million. The company earns $-13,280,000.00 in net income (profit) each year or ($5.25) on an earnings per share basis. ANCHIANO THERAP/S employs 19 workers across the globe.View Additional Information About ANCHIANO THERAP/S.

What is ANCHIANO THERAP/S's official website?

The official website for ANCHIANO THERAP/S is http://www.anchiano.com/.

How can I contact ANCHIANO THERAP/S?

ANCHIANO THERAP/S's mailing address is 1/3 HIGH-TECH VILLAGE GIVAT RAM P.0. BOX 39264, JERUSALEM L3, 9139102. The company can be reached via phone at 972-2548-6555 or via email at [email protected]


MarketBeat Community Rating for ANCHIANO THERAP/S (NASDAQ ANCN)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  44 (Vote Outperform)
Underperform Votes:  50 (Vote Underperform)
Total Votes:  94
MarketBeat's community ratings are surveys of what our community members think about ANCHIANO THERAP/S and other stocks. Vote "Outperform" if you believe ANCN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ANCN will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/6/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel